Pomerantz Law Firm Announces the Filing of a Class Action Against Bolt Biotherapeutics, Inc. and Certain Officers - BOLT

Historically, Bolt's lead asset was BDC-1001, which had pre-defined success criteria that included an overall response rate efficacy threshold of at least 30% and, according to Bolt, purportedly "provide[d] a compelling example of the potential of Boltbody ISACs to address unmet medical needs in solid tumors" by "targeting HER2-expressing tumors and related metastatic disease, triggering their destruction by the innate and adaptive immune systems." Pomerantz LLP, with offices in New York, Chicago, Los Angel ...